Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)
Status:
NOT_YET_RECRUITING
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the effect of multiple doses of vimseltinib on the pharmacokinetics (PK) of a clinical OCT2 substrate (metformin) in healthy male participants. This study will also assess the safety and tolerability when vimseltinib is co-administered with the clinical OCT2 substrate (metformin) in healthy male participants. This study will last approximately 25 days.